Endolymphatic hydrops perspectives 2012.
OBJECTIVE
Endolymphatic hydrops remains a significant cause of morbidity secondary to vertigo, hearing loss, and tinnitus. The purpose of this report is to summarize the most clinically relevant publications on endolymphatic hydrops over the past 2 years.


RESULTS
Hydrops has historically been a diagnosis of exclusion, but recent efforts has shown a role for MRI with intratympanic gadolinium. Cochrane reviews of intratympanic dexamethasone and gentamicin found inadequate level 1 evidence to support their use.


CONCLUSIONS
High-level evidence to guide therapy is lacking. MRI holds potential for definitive diagnosis.
Department of Otolaryngology, University of Florida, Gainesville, Florida, USA.
Nathan E
NE
Pierce
Patrick J
PJ
Antonelli
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003287:Contrast Media; D018159:Endolymphatic Hydrops / Q000150:complications / Q000175:diagnosis*; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D018570:Risk Assessment; D014012:Tinnitus / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D016896:Treatment Outcome; D014717:Vertigo / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D003287:Contrast Media